Clinical trials: COVID-19 Booster
COVID-19 Vaccines
Randomized, Single-blinded, Multicenter Trial Comparing the Immune Response to a 2nd Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNTech) or Sanofi /GSK B.1.351 Adjuvanted Vaccine in Adults
The effectiveness of COVID-19 vaccines in reducing the risk of severe COVID-19 is currently demonstrated. In France, since the beginning of the vaccination campaign, 54,266,859 people have received at least one injection (ie.
- Trial name
- COVIBOOSTAnci1 (NCT05405283)
- Testing
- 2nd booster with Comirnaty® (Pfizer-BioNTech), CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK
- Where
- France
- Volunteers
- 189 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
COVID-19
Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers.
The goal of this clinical trial, on healthy volunteers, is to learn more about safety and reactogenicity of the CD40.RBDv vaccine.
- Trial name
- NCT06255626
- Testing
- CD40.RBDv vaccin (SARS-Cov2 Vaccin)
- Where
- 2 sites in France
- Volunteers
- 215 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
COVID-19, SARS-CoV-2
Safety and Immunogenicity of COVI-VAC as a Booster Dose in Adults Previously Vaccinated Against COVID-19
The purpose of this study is to to evaluate the safety and immune response of COVI-VAC given as a single booster dose in healthy adults previously vaccinated against COVID-19 with an authorised mRNA or adenovirus-vectored…
- Trial name
- NCT05233826
- Testing
- COVI-VAC
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Codagenix, Inc
COVID-19
Phase II Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell)
A single-center, randomized, double-blind, controlled clinical trial to evaluate the safety and immunogenicity of booster vaccination of Recombinant COVID-19 variant vaccine (Sf9 cell) in healthy people aged 18 years and older…
- Trial name
- NCT05770180
- Testing
- Recombinant COVID-19 variant vaccine (Sf9 cell), Recombinant COVID-19 vaccine (CHO cell), Recombinant COVID-19 vaccine (Sf9 cell)
- Where
- China
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- WestVac Biopharma Co., Ltd.
SARS-CoV-2 Infection
Ad26.COV2.S as a Heterologous Booster in Adults After Single- or Two-Dose of Inactivated COVID-19 Vaccine
This study aims to address evidence gaps regarding the safety, reactogenicity and immune responses of a heterologous boost of a single dose of Ad26.COV2.S (half or full dose) at pre-specified time intervals in recipients who are…
- Trial name
- NCT05109559
- Testing
- Full dose of Ad26.COV2. 5x10^10vp, Half dose of Ad26.COV2. 2.5x10^10vp
- Where
- Thailand
- Volunteers
- 690 people, healthy volunteers welcome
- Sponsor
- Mahidol University
COVID-19
Efficacy,Immunogenicity and Safety of COVID-19 Vaccine , Inactivated Booster Dose in Adults Aged 18 Years and Above
This is a multi-center, case-driven, randomized, double-blinded, and placebo-controlled Phase Ⅲb clinical trial of COVID-19 Vaccine manufactured by Sinovac Research \& Development Co., Ltd.The purpose of this study is to evaluate…
- Trial name
- NCT05156632
- Testing
- Medium-dosage COVID-19 Vaccine,Inactivated, High-dosage COVID-19 Vaccine,Inactivated
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
COVID-19
Reactogenicity and Immunogenicity of Third Dose Vaccine Booster Following Two Doses of Inactivated Vaccines
It is a prospective open-labeled study, We intended to recruit the participants who completed 2 doses of inactivated COVID-19 vaccine 4-8 months before, and volunteered to receive the third dose of vaccine (inactivated vaccine…
- Trial name
- NCT05095298
- Testing
- Vaccine, COVID19
- Where
- 2 sites in China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Huashan Hospital
COVID-19 Vaccine, COVID-19
Evaluation of Safety, Tolerability, Reactogenicity, Immunogenicity of Baiya SARS-CoV-2 Vax 2 as a Booster for COVID-19
The investigational product Baiya SARS-CoV-2 Vax 2 vaccine is a second-generation of protein subunit vaccine from plant to prevent COVID-19 disease.
- Trial name
- NCT05873374
- Testing
- 50 μg Baiya SARS-CoV-2 Vax 2
- Where
- Thailand
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Baiya Phytopharm Co., Ltd.
COVID-19
Trial of 2nd Booster Dose of COVID-19 Vaccine
Background Recent studies indicate that a 2nd booster dose is associated with lower risk of severe COVID-19. The studies are based on Israeli registry data, comparing outcomes among individuals who have taken the booster, or not.
- Trial name
- NCT05539703
- Testing
- Invitation to get a 2nd booster dose of COVID-19 vaccine
- Volunteers
- healthy volunteers welcome
- Sponsor
- Norwegian Institute of Public Health
SARS-CoV-2
A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters
The main goal of Part A of this study is to assess the safety, reactogenicity, and immunogenicity of the study vaccine candidates.
- Trial name
- NCT05137236
- Testing
- mRNA-1283, mRNA-1283.211, mRNA-1273
- Where
- 17 sites in United States
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
COVID-19 (Healthy Volunteers)
Safety, Reactogenicity, and Immunogenicity Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510)
This is randomized, placebo-controlled, observer-blinded, multi-center study to assess safety, reactogenicity and immunogenicity of booster vaccination of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted…
- Trial name
- NCT05175950
- Testing
- SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) (RBD of SARS-CoV-2 25ug / dose) Adjuvanted with AS03, Normal saline
- Where
- 9 sites in South Korea
- Volunteers
- 770 people, healthy volunteers welcome
- Sponsor
- Korea University Guro Hospital
COVID-19, Vaccine Reaction
The Immunogenicity and Safety Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB001
The goal of this clinical trial is to assess the immunogenicity and safety following a heterologous booster dose of recombinant SARS-CoV-2 vaccine (CHO cell) LYB001 in adults 18-59 years of age completed two- or three-dose…
- Trial name
- NCT05928455
- Testing
- LYB001, CoronaVac
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
SARS-CoV-2
A Study to Determine Antibody Levels After Receiving COVID-19 Boosters of Any Kind
This study will investigate antibody levels with respect to time since receiving a COVID-19 booster shot. The study will be decentralized, where participants can complete all study tasks at home.
- Trial name
- disCOVEries (NCT05367908)
- Where
- United States
- Volunteers
- 1,501 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
COVID-19
Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac®) Vaccine in Healthy Adults in Turkey
This is a randomized, double-blinded, and positive-controlled Phase IIb clinical trial of COVID-19 vaccine (CoronaVac®) manufactured by Sinovac Research \& Development Co., Ltd.The purpose of this study is to evaluate the…
- Trial name
- NCT05150496
- Testing
- Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated, High-dose COVID-19 Vaccine(Vero Cell),Inactivated
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 640 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
COVID-19
Heterologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine in Children 12-17 Years of Age
The goal of this clinical trial is to evaluate immune response and safety of SARS-CoV-2 subunit protein recombinant vaccine (IndoVac) as a heterologous booster dose in healthy children 12-17 years of age.
- Trial name
- NCT05727215
- Testing
- SARS-CoV-2 subunit protein recombinant vaccine
- Where
- Indonesia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Ebola Virus Disease, COVID-19
Safety and Immunogenicity of rVSVΔG-ZEBOV-GP Vaccination When Dosed Concurrently With mRNA COVID-19 Vaccine Booster Doses
Concurrent vaccination scheduling for key target populations in Rwanda, such as healthcare workers, may confer significant advantages in the provision of vaccine coverage to several infectious diseases.
- Trial name
- NCT06587503
- Testing
- BioNTech - Pfizer COVID-19 vaccine, 1mL saline solution, rVSV∆G-ZEBOV-GP
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University of Birmingham
COVID-19, SARS-CoV-2 Acute Respiratory Disease
Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Healthy Adults Volunteers Fully Vaccinated Followed by an Extension Period to Study a Fourth Dose Administration.
This Phase IIb clinical study aims to compare the immunogenicity and safety of a booster dose of recombinant protein RBD fusion dimer vaccine as a heterologous booster (to subjects who have received the second dose of the…
- Trial name
- NCT05142553
- Testing
- COVID-19 Vaccine HIPRA, Cominarty (Pfizer-BioNtech)
- Where
- 10 sites in Spain
- Volunteers
- 887 people, healthy volunteers welcome
- Sponsor
- Hipra Scientific, S.L.U
COVID-19 Pandemic, COVID-19 Vaccines
UNAIR Inactivated COVID-19 Vaccine INAVAC as Heterologue Booster (Immunobridging Study) in Adolescent Subjects
This is an open label trial. There will only be 1 group in the study. All subjects will receive INAVAC vaccine and be followed for 6 months. The vaccine will be administered intramuscularly.
- Trial name
- NCT06272253
- Testing
- INAVAC (Vaksin Merah Putih - UA- SARS CoV-2 (Vero Cell Inactivated) 5 μg
- Where
- Indonesia
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Dr. Soetomo General Hospital
SARS CoV 2 Infection
Phase II Study of AVX/COVID-12 Vaccine in Subjects With Prior SARS-CoV-2 Immunity Evidence
This is a Phase II study with single-blinded safety phase followed by double-blinded randomization, placebo-controlled, of administration of a single dose by two different administration routes (intramuscular route or intranasal…
- Trial name
- NCT05205746
- Testing
- Recombinant NDV Vectored Vaccine for SARS-CoV-2
- Where
- 4 sites in Mexico
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Laboratorio Avi-Mex, S.A. de C.V.
COVID-19
Understanding Adaptive Immune Response After COVID-19 Vaccination Boosters to Improve Vaccination Strategies in Vulnerable Groups.
This is an experimental study without drug and device, non-profit, single-center. The general objective of the project is to study how the adaptive immune response evolves against SARS-CoV-2 with repeated vaccination boosters and…
- Trial name
- COVaxFragile (NCT06300853)
- Testing
- Analisys of cellular response and humoral response to SARS-CoV-2 vaccine booster doses
- Where
- Italy
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- IRCCS Sacro Cuore Don Calabria di Negrar